CD8A and neoplasm: This mechanism might explain why certain patients do not respond to therapies based on immune-checkpoint blockade as well as it provides new insights in possible strategies to revert non-reprogrammable PD-1 high T cells into tumor-reactive CD8 + T cells (Fig. 2, Table 1).